Leukemia / Lymphoma Clinical Trials

 

St. Jude Clinical Trials

ALLR18: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Diseases Treated:

Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

Eligibility:

  • B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has:
    • Come back after treatment the first time
    • Did not respond to treatment the first time
  • Less than 22 years of age
  • Does not have HIV or hepatitis B infection
View Trial

AML08: Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

A Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and of Natural Killer Cell Transplantation Versus Conventional Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Diseases Treated:

Acute myeloid leukemia (AML)

Eligibility:

  • 21 years of age or younger at the time of study entry
  • No prior therapy for AML except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine for hyperleukocytosis
  • Must not have Down syndrome, acute promyelocytic leukemia (APL), juvenile myelomonocytic leukemia (JMML), Fanconi anemia (FA), Kostmann syndrome, Shwachman syndrome and other  bone marrow failure syndromes
View Trial

BECHEM: Bendamustine, Clofarabine and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies

A Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies

Diseases Treated:

Relapsed or refractory hematologic malignancies

Eligibility:

  • Diagnosis of Hodgkin lymphoma, non-Hodgkin lymphoma or leukemia that has come back or did not respond to treatment
  • Must be 21 years of age or younger at the time of enrollment
  • Must have adequate kidney and heart function 
View Trial

FAMHL: Genetic Study of Families with Hodgkin Lymphoma

Genetic Study of Families with High Frequency of Hodgkin Lymphoma

Diseases Treated:

Hodgkin lymphoma

Eligibility:

  • 21 years of age or younger
  • Patient has a parent, sister, brother or child who also has Hodgkin lymphoma
  • Patient’s other family members who agree to participate

 

View Trial

HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma

Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies

Diseases Treated:

Leukemia/Lymphoma

Eligibility:

  • 21 years and younger
  • Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
  • Has a suitable single haplotype-matched family member donor
  • High-risk hematologic malignancy, including certain diagnoses of:
    • Acute lymphoblastic leukemia (ALL)
    • Acute myeloid leukemia (AML)
    • Chronic myelogenous leukemia (CML)
    • Myelodysplastic syndrome (MDS)
    • Hodgkin lymphoma
    • Non-Hodgkin lymphoma
View Trial

HLHR13: Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma

Adcetris® (Brentuximab Vedotin) Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High-Risk Pediatric Hodgkin Lymphoma (HL)

Diseases Treated:

High-risk Hodgkin lymphoma

Eligibility:

  • Has high-risk Hodgkin lymphoma
  • 18 years of age or younger
  • Has not received previous treatment for Hodgkin lymphoma
View Trial

HOD08: Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma

Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma

Diseases Treated:

Hodgkin lymphoma

Eligibility:

  • Diagnosis of early-stage Hodgkin lymphoma 
  • Hodgkin lymphoma that has not been previously treated
  • 21 years of age or younger
View Trial

MITREL: A Phase II Study of Microtransplantation in Patients with Refractory or Relapsed Hematologic Malignancies

A Phase II Study of Microtransplantation in Patients with Refractory or Relapsed Hematologic Malignancies

Diseases Treated:

Refractory or relapsed acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)

Eligibility:

  • Patient should be is less than or equal to twenty-one years of age.
  • Patient has a diagnosis of AML or MDS that has relapsed or is refractory to chemotherapy or has relapsed after HSCT.
  • Patient has an available HPC-A donor.
View Trial

NHL16: Study for Newly Diagnosed Patients with Acute Lymphoblastic Lymphoma

Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Lymphoma

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

  • 21 years of age or younger
  • Newly diagnosed lymphoblastic lymphoma
  • Has received one week or less prior treatment for lymphoblastic lymphoma
View Trial

PANAML: Panobinostat, Fludarabine and Cytarabine in Patients with AML or MDS

A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination with Fludarabine and Cytarabine in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Diseases Treated:

Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)

Eligibility:

  • Diagnosis of AML or MDS that has come back or did not respond to chemotherapy
  • 21 years of age or younger at time of enrollment
  • Able to swallow capsules
  • Recovered from side effects of previous cancer therapy
View Trial

REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

Diseases Treated:

Eligibility:

  • 21 years old and younger
  • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
    • Acute lymphoblastic leukemia (ALL)
    • Acute myeloid leukemia
    • Myeloid sarcoma
    • Chronic myeloid leukemia (CML)
    • Juvenile myelomonocytic leukemia (JMML)
    • Myelodysplastic syndrome (MDS)
    • Non-Hodgkin lymphoma (NHL)
  • Has a family member who is a suitable stem cell donor
View Trial

RELHEM2: Crenolanib and Sorafenib Tosylate in Treating Patients with Refractory or Relapsed Hematologic Malignancies

A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination with Sorafenib in Patients with Refractory or Relapsed Hematologic Malignancies (ARO-008)

Diseases Treated:

Refractory or relapsed hematologic malignancies (leukemia)

Eligibility:

  • Between the ages of 1 and 25 years
  • FLT3-mutated AML that has returned or did not respond to previous chemotherapy
  • No history of HIV infection, hepatitis B, or hepatitis C
View Trial

RELMLL: A Phase II Study of Bortezomib and Vorinostat in Patients with Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Diseases Treated:

Relapsed or refractory leukemia / lymphoma

Eligibility:

This clinical trial has both inclusion and exclusion criteria. See Eligibility Requirements in the full trial for specifics.

View Trial

SELHEM: Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination with Fludarabine and Cytarabine in Patients with Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Diseases Treated:

Relapsed or refractory leukemia or hematologic malignancies

Eligibility:

  • Up to 21 years of age
  • Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) or mixed phenotype acute leukemia (MPAL) that has come back or did not respond to previous treatment
  • No history of HIV infection
View Trial

SJBC3: Mature B-cell Lymphoma and Leukemia Study III

Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia

Diseases Treated:

Leukemia and lymphoma

Eligibility:

  • 21 years of age or younger
  • Newly diagnosed mature B-cell non-Hodgkin lymphoma and leukemia
  • Has not been previously treated
View Trial

TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

Diseases Treated:

Acute lymphoblastic leukemia (ALL)

Eligibility:

  • Newly diagnosed ALL
  • 1 year of age or younger at the time of diagnosis
  • Has not had any — or has had limited — prior therapy
  • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
View Trial

TOTXVI: Total Therapy Study XVI For Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Diseases Treated:

Acute Lymphoblastic Leukemia

Eligibility:

  • 18 years of age or younger
  • Newly diagnosed acute lymphoblastic leukemia (ALL)
View Trial

TSALV: Advanced Chemotherapy Treatment for Relapsed Leukemia or Lymphoma in Children

A Phase II Study Incorporating Panobinostat, Bortezomib, and Liposomal Vincristine into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Diseases Treated:

Leukemia, Lymphoma

Eligibility:

  • T-call acute lymphoblastic leukemia or lymphoma that has:
    • Come back after treatment the first time or
    • Did not respond to treatment the first time
  • 21 years or younger
  • Able to swallow capsules
View Trial

Collaborative Clinical Trials

ADV1212: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

A Phase I Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Diseases Treated:

Relapsed or refractory solid tumors or anaplastic large cell lymphoma

Eligibility:

  • Participant is > than 12 month and < 21 years of age at the time of enrollment.
  • Participant has histologic verification at original diagnosis or relapse or relapse of relapsed or refractory solid tumor or anaplastic large cell lymphoma (ALCL).
  • Participant does not have primary or metastatic CNS tumor.
  • Participant has not received prior therapy with crizotinib.
View Trial

HODLP: First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin Lymphoma in Children and Adolescents

Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Diseases Treated:

Lymphocyte predominant Hodgkin lymphoma 

Eligibility:

  • Diagnosis of early-stage lymphocyte-predominant Hodgkin lymphoma (LPHL)
  • LPHL that has not been previously treated with chemotherapy or radiation therapy
  • 18 years of age or younger

 

View Trial

LDTAM: Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

Diseases Treated:

For survivors of Hodgkin lymphoma

Eligibility:

  • Females, 25 years of age or older.
  • Participant does not plan to become pregnant in the next 2 years and is not currently breast feeding.
View Trial

NECTAR: Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide) in T-ALL Relapse: A Joint Study of TACL and POETIC

Diseases Treated:

Leukemia

Eligibility:

  • Patients must be ≥ 1 and ≤ 21 years of age at the time of study enrollment.
  • Patients must have first relapse T-cell ALL or T-cell lymphoblastic lymphoma.
  • Patients with T-cell ALL must have greater than 25% blasts in the bone marrow with or without extramedullary disease.
  • Patients with T-cell ALL must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis.
View Trial

TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

Diseases Treated:

Acute lymphoblastic leukemia (ALL)

Eligibility:

  • Newly diagnosed ALL
  • 1 year of age or younger at the time of diagnosis
  • Has not had any — or has had limited — prior therapy
  • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
View Trial